<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03645603</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2015-002114-80 OsSC</org_study_id>
    <nct_id>NCT03645603</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Dexmedetomidine During Weaning From Analgesia and Sedation in PICU (TIP-15-01)</brief_title>
  <acronym>TIP-15-01</acronym>
  <official_title>Efficacy and Safety of Dexmedetomidine During Weaning From Analgesia and Sedation in Pediatric Intensive Care Unit. A Multicenter, Double-blind, Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera di Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This interventional study evaluates the efficacy of dexmedetomidine during weaning from
      analgesic and sedative drugs in reducing the occurrence of the withdrawal syndrome in PICU.
      All enrolled patients will undergo the same weaning regimen one half will receive
      dexmedetomidine while the other will receive a placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children admitted to PICU need of analgesic and sedative drugs. Prolonged treatment can lead
      to undesirable effects as dependence and tolerance. Patients that have developed dependence
      may develop the withdrawal syndrome (WS) during the analgesics and sedatives weaning process.

      Withdrawal symptoms are due to central nervous system excitement, gastrointestinal
      disturbance, and sympathetic system activation. The incidence of withdrawal syndrome is
      variable between 17 and 57% a recent study reported an incidence of 64.6% of WS in Italian
      PICUs. The prevention strategies are addressed to the restriction of drug exposure and to the
      gradual tapering of infusion. However, these strategies have weak evidence of effectiveness.
      In this study, the investigators hypothesize that dexmedetomidine may be useful and effective
      during the weaning of analgosedation drugs in PICU, in preventing the withdrawal syndrome.
      The primary aim of the study is to evaluate the efficacy of dexmedetomidine in reducing the
      occurrence of the WS. Secondary aims are to evaluate the dexmedetomidine safety during the
      weaning, the effective dose range, and the efficacy in reducing the duration of the weaning,
      of the mechanical ventilation, and of the length of PICU stay. Efficacy will be compared
      among pediatric age groups, gender, race, Pediatric Index of Mortality (PIM3) score, and
      length of the analgosedation treatment.

      Patients admitted to the PICU that meets the inclusion criteria, will be randomly assigned to
      one of the two treatment groups: treatment A (dexmedetomidine) or treatment B (placebo).

      Twenty-four hours before the start of the weaning an intravenous infusion of
      dexmedetomidine/placebo will start. After 24 hours of dexmedetomidine infusion, the weaning
      regimen will begin following the subsequent indications: 10% reduction of the dose every 12
      hours. The withdrawal assessment tool version 1 (WAT-1) is the selected scale to evaluate the
      occurrence of the WS. Patients with a score of WAT-1 &lt;3 continue the weaning regimen.
      Patients with a score ≥3 increase the dose of dexmedetomidine/placebo until the next WAT-1
      score control and temporarily stop the planned 10% dose reduction. If the next WAT-1 score
      decreased by at least 1 point from the previous score, the weaning program restarted (10%
      reduction) without further changes in the dose of dexmedetomidine/placebo until the
      subsequent score. The 'acute withdrawal crisis' will be treated with a rescue dose of the
      opioid and/or benzodiazepine in use repeatable until resolution of the crisis. Once
      analgesics and sedatives weaning is complete, dexmedetomidine will gradually discontinue.
      Five days after discharge from PICU, a follow-up visit will be performed.

      The sample size estimate is 80 participants for each of the two groups for a total of 160
      patients recruited within a period of two years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Withdrawal Assessment Tool (WAT-1) scale</measure>
    <time_frame>time 0 start dexmedetomidine and every 12 hours post-start dexmedetomidine for 7 days</time_frame>
    <description>WAT-1 score recorded every 12 hours.The score ranges from 0 to 12, a score ≥3 indicates the presence of signs/symptoms of withdrawal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>0,1, 2, 12, 24 hours post-start dexmedetomidine and then every 12 hours for 7 days</time_frame>
    <description>changes in heart rate will be recorded when their value differs more than 20% by the patient's baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure</measure>
    <time_frame>0,1, 2, 12, 24 hours post-start dexmedetomidine and then every 12 hours for 7 days</time_frame>
    <description>changes in Systolic Blood Pressure will be recorded when their value differs more than 20% by the patient's baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure</measure>
    <time_frame>0,1, 2, 12, 24 hours post-start dexmedetomidine and then every 12 hours for 7 days</time_frame>
    <description>changes in Diastolic Blood Pressure will be recorded when their value differs more than 20% by the patient's baseline values.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Opioid dose</measure>
    <time_frame>7 days</time_frame>
    <description>verification of adherence to weaning regimen</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Sedative dose</measure>
    <time_frame>7 days</time_frame>
    <description>verification of adherence to weaning regimen</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Withdrawal Syndrome</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 100 mcg/ml concentrate solution. Continuous iv infusion. Start dose 0.4 mcg/kg/h, increases by 0.2 mcg/kg/h until 0.8 mcg/kg/h (half dose for neonates). If withdrawal symptoms appear the dose can be increased to a maximum of 1.4 mcg/Kg/h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline solution for IV infusion. The administration of infusion will follow the experimental drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Dexdor, Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intravenous infusion of physiological saline solution to mimic dexmedetomidine infusion</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>physiological saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Continuous analgesic and sedative endovenous treatment for at least 5 days

          -  Invasive or non-invasive mechanical ventilation

          -  Clinical conditions that allow by clinical judgment the start of analgosedation
             weaning

          -  Post-natal age ≥ 7 days and PMA beyond the 37 weeks

          -  Written informed consent obtained

        Exclusion Criteria:

          -  Hemodynamic instability

          -  Cardiac bundle-branch block of 2 or 3 degree

          -  Hypersensitivity to the alpha-agonists

          -  Persistent fever of unknown origin or sensitivity to malignant hyperthermia

          -  Use of alpha-agonist (clonidine or dexmedetomidine) in the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria C. Mondardini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda Ospedaliero Universitaria di Bologna Policlinico S.Orsola-Malpighi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria C. Mondardini, MD</last_name>
    <phone>0512143650</phone>
    <phone_ext>0039</phone_ext>
    <email>mariacristina.mondardini@aosp.bo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angela Amigoni, MD</last_name>
    <phone>0498213595</phone>
    <phone_ext>0039</phone_ext>
    <email>angela.amigoni@aopd.veneto.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>PICU Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria C. Mondardini, MD</last_name>
      <phone>0512143650</phone>
      <phone_ext>0039</phone_ext>
      <email>mariacristina.mondardini@aosp.bo.it</email>
    </contact>
    <contact_backup>
      <last_name>Angela Amigoni, MD</last_name>
      <phone>0498213595</phone>
      <phone_ext>0039</phone_ext>
      <email>angela.amigoni@aopd.veneto.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Amigoni A, Mondardini MC, Vittadello I, Zaglia F, Rossetti E, Vitale F, Ferrario S, Savron F, Coffaro G, Brugnaro L, Amato R, Wolfler A, Franck LS; Network of Paediatric Intensive Care Unit Study Group (TIPNet). Withdrawal Assessment Tool-1 Monitoring in PICU: A Multicenter Study on Iatrogenic Withdrawal Syndrome. Pediatr Crit Care Med. 2017 Feb;18(2):e86-e91. doi: 10.1097/PCC.0000000000001054.</citation>
    <PMID>28157809</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</investigator_affiliation>
    <investigator_full_name>Maria Cristina Mondardini</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pediatrics</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>analgesia</keyword>
  <keyword>sedation</keyword>
  <keyword>pediatric intensive care unit</keyword>
  <keyword>abstinence syndrome</keyword>
  <keyword>assessment tool</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03645603/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

